IL6 and Sepsis: In terms of sepsis-associated kidney injury, the miR-155 inhibitor alleviates LPS-induced kidney injury by decreasing the levels of TNF-α and IL-6 in renal tissues and the mortality of LPS-treated mice, indicating that miR-155 may be a potential therapeutic target for treatment of sepsis-related kidney injury [96].